Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes

European Urology

Volumn 49, Issue 3, 2006, Pages 528-535

  Kalsi, Vinay ^a   Apostolidis, Apostolos ^a   Popat, Roshni ^a   Gonzales, Gwendoline ^a   Fowler, Clare J ^a   Dasgupta, Prokar ^a,b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Bladder; Botulinum toxin; Detrusor overactivity; Quality of life

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; DESMOPRESSIN; OXYBUTYNIN; TOLTERODINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTOMETRY; FOLLOW UP; HUMAN; INCONTINENCE; MICTURITION; NEUROGENIC BLADDER; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; URINARY TRACT DISEASE; URODYNAMICS;

ADULT; BOTULINUM TOXIN TYPE A; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; NEUROMUSCULAR AGENTS; QUALITY OF LIFE; QUESTIONNAIRES; URINARY BLADDER, NEUROGENIC; URINARY INCONTINENCE; URINATION DISORDERS; URODYNAMICS;

EID: 32944482040     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.12.012     Document Type: Article

References (26)

1. A. Sahai, M. Khan, C.J. Fowler, and P. Dasgupta Botulinum toxin for the treatment of lower urinary tract symptoms: a review Neurourol Urodyn 24 2005 2 12
2. A. Reitz, M. Stohrer, G. Kramer, G. Del Popolo, E. Chartier-Kastler, and J. Pannek European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity Eur Urol 45 2004 510 515
3. B. Schurch, M. de Seze, P. Denys, E. Chartier-Kastler, F. Haab, and K. Everaert Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study J Urol 174 2005 196 200
4. R. Popat, A. Apostolidis, V. Kalsi, G. Gonzales, C.J. Fowler, and P. Dasgupta A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin J Urol 174 2005 984 988
5. D.E. Rapp, A. Lucioni, E.E. Katz, R.C. O'Connor, G.S. Gerber, and G.T. Bales Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience Urology 63 2004 1071 1075
6. C.P. Smith, J. Nishiguchi, M. O'Leary, N. Yoshimura, and M.B. Chancellor Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra Urology 65 2005 37 41
7. M.K. Flynn, G.D. Webster, and C.L. Amundsen The effect of botulinum-a toxin on patients with severe urge urinary incontinence J Urol 172 2004 2316 2320
8. B. Schurch, M. Stohrer, G. Kramer, D.M. Schmid, G. Gaul, and D. Hauri Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results J Urol 164 2000 692 697
9. C.R. Chapple, W. Artibani, L.D. Cardozo, D. Castro-Diaz, M. Craggs, and F. Haab The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects BJU Int 95 2005 335 340
10. K.S. Coyne, C. Payne, S.K. Bhattacharyya, D.A. Revicki, C. Thompson, and R. Corey The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey Value Health 7 2004 455 463
11. A. Apostolidis, R. Popat, Y. Yiangou, D. Cockayne, A.P. Ford, and J.B. Davis Decreased sensory receptors P2x3 and Trpv1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity J Urol 174 2005 977 983
12. S.C. Radley, D.J. Rosario, C.R. Chapple, and A.G. Farkas Conventional and ambulatory urodynamic findings in women with symptoms suggestive of bladder overactivity J Urol 166 2001 2253 2258
13. H. Schulte-Baukloh, C. Weiss, T. Stolze, B. Sturzebecher, and H.H. Knispel Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction Urology 66 2005 82 87
14. J.S. Uebersax, J.F. Wyman, S.A. Shumaker, D.K. McClish, and J.A. Fantl Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group Neurourol Urodyn 14 1995 131 139
15. J. Donovan, R. Bosch, M. Gotoh, S. Jackson, M. Naughton, and S. Radley Symptom and quality of life assessment P. Abrams L. Cardozo S. Khoury A. Wein Incontinence 2005 Health Publications Paris 519 584
16. P. Abrams, L. Cardozo, M. Fall, D. Griffiths, P. Rosier, and U. Ulmsten The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 21 2002 167 178
17. M. Harper, R. Popat, R. DasGupta, C.J. Fowler, and P. Dasgupta A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity BJU Int 92 2003 325 326
18. C.J. Fowler Investigation of the neurogenic bladder J Neurol Neurosurg Psychiatry 60 1996 6 13
19. H.C. Kuo Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics Urology 66 2005 94 98
20. G.E. Lemack, and P.E. Zimmern Predictability of urodynamic findings based on the Urogenital Distress Inventory-6 questionnaire Urology 54 3 1999 461 466
21. M.P. FitzGerald, and L. Brubaker Urinary incontinence symptom scores and urodynamic diagnoses Neurourol Urodyn 21 2002 30 35
22. G. Matharu, M.M. Donaldson, C.W. McGrother, and R.J. Matthews Relationship between urinary symptoms reported in a postal questionnaire and urodynamic diagnosis Neurourol Urodyn 24 2005 100 105
23. L.K. Daha, C.R. Riedl, D. Lazar, G. Hohlbrugger, and H. Pfluger Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis? Eur Urol 47 2005 393 397 discussion 397
24. M.P. FitzGerald, N. Butler, S. Shott, and L. Brubaker Bother arising from urinary frequency in women Neurourol Urodyn 21 1 2002 36 40 discussion 41
25. P.J. Woodman, C.A. Misko, and J.R. Fischer The use of short-form quality of life questionnaires to measure the impact of imipramine on women with urge incontinence Int Urogynecol J Pelvic Floor Dysfunct 12 2001 312 315 discussion 315-6
26. S. Hagen, J. Hanley, and A. Capewell Test-retest reliability, validity, and sensitivity to change of the urogenital distress inventory and the incontinence impact questionnaire Neurourol Urodyn 21 2002 534 539